Real-world Data in Patients With Breast Cancer Treated With Abemaciclib (ENDURANCE)
Real-world Clinical Outcome and Toxicity Data in Patients With Breast Cancer Treated With Abemaciclib Combined With Endocrine Therapy: the Experience of the Hellenic Cooperative Oncology Group
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Elena Fountzilas, MD, PhD
- Phone Number: +306945779709
- Email: FOUNTZILA@ONCOGENOME.GR
Study Contact Backup
- Name: Areti Stamboliou
- Phone Number: 23 +302106912520
- Email: a_stampoliou@hecog.ondsl.gr
Study Locations
-
-
-
Athens, Greece
- Recruiting
- Hellenic Oncology Cooperative Group
-
Contact:
- Elena Fountzilas, MD
- Email: fountzila@oncogenome.gr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Histologically confirmed HR-positive, HER2-negative breast cancer
- Treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology
- 18 years or older
- Any menopausal status
- Treatment with abemaciclib in combination with endocrine therapy
- Any endocrine therapy
- At least two months of treatment with abemaciclib
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Patients with breast cancer randomised in arm A of digital platform
Patients with breast cancer treated with abemaciclib in combination with endocrine treatment and randomised in Arm A of the digital platform.
Patients randomised in arm A will receive a an acknowledgement and suggestion to stay in contact with their clinician.
|
|
Patients with breast cancer randomised in arm B of digital platform
Patients with breast cancer treated with abemaciclib in combination with endocrine treatment and randomised in Arm B of the digital platform.
Patients randomised in arm A will receive a an acknowledgement and suggestion to stay in contact with their clinician; additionally they will receive personalised support (as a few word text) for each side-effect reported.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression-free survival
Time Frame: Through the completion of the study, for an average of 6 months
|
the time from treatment initiation to either the first documented disease progression or death from any cause
|
Through the completion of the study, for an average of 6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival
Time Frame: From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 96 months
|
The time from treatment initiation to patient death or last contact
|
From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 96 months
|
|
Efficacy of the digital support through personalised support in patients with BC
Time Frame: Up to 30 months
|
Up to 30 months
|
|
|
Toxicity rate
Time Frame: Up to 30 months
|
Adverse events from the time from treatment initiation to disease progression, patient death or last contact
|
Up to 30 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ΗΕ_11ΑΒ/21
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.